Big Move For PhaseBio Pharmaceuticals, Inc.
PhaseBio Pharmaceuticals, Inc. (PHAS:NASDAQ) rocketted at $1.68, representing a gain of 46.1%. The stock got featured on our News Catalysts scanner on Thu, Mar 24, 2022 at 05:15 PM in the 'EARNINGS' category. From Mon, Mar 14, 2022, the stock recorded 70.00% Up Days and 54.55% Green Days
About PhaseBio Pharmaceuticals, Inc. (PHAS:NASDAQ)
PhaseBio Pharmaceuticals Inc is a clinical-stage bio-pharmaceutical company. It is focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications. The lead product candidate of the company is PB2452, which is a novel reversal agent for the antiplatelet drug ticagrelor, used for the treatment of patients experiencing major bleeding or those who require urgent surgery. It is also developing PB1046, a fusion protein currently in a Phase 2b clinical trial for the treatment of pulmonary arterial hypertension.
Top 10 Gainers:
- IGM Biosciences, Inc. (IGMS:NASDAQ), 96.73%
- PhaseBio Pharmaceuticals, Inc. (PHAS:NASDAQ), 46.09%
- China SXT Pharmaceuticals, Inc. (SXTC:NASDAQ), 45.4%
- Oblong Inc. (OBLG:NASDAQ), 45%
- Clever Leaves Holdings Inc. (CLVR:NASDAQ), 40.31%
- MicroVision, Inc. (MVIS:NASDAQ), 32.78%
- ECMOHO Limited (MOHO:NASDAQ), 27.95%
- LianBio (LIAN:NASDAQ), 27.5%
- BBQ Holdings, Inc. (DAVE:NASDAQ), 27.45%
- Kinnate Biopharma Inc. (KNTE:NASDAQ), 25.94%